Les articles qui suivent, portant sur divers travaux menés par la Compagnie, ont été publiés par certain des employés, principaux chercheurs et investigateurs de Neurochem, ainsi qu'autres collaborateurs externes. Nous vous invitons également à prendre connaissance de certains des résumés scientifiques présentés par ces chercheurs ou autres spécialistes, lors de congrès scientifiques internationaux.

• Greenberg, S., Rosand, J., Schneider, A., Creed Pettigrew, L., Gandy, S., Rovner, B., Fitzsimmons, B-F., Smith, E., Gurol, E., Schwab, K., Laurin, J., and Garceau, D.
  "A Phase II Study of Trampiprosate for Cerebral Amyloid Angiopathy."
  ADAD: In press.
  
  

• Sebastiani, G., Kryzwkowski, P., Dudal, S., Yu, M., Paquette, J., Malo, D., Gervais, F., Tremblay, P. 2006.
  "Mapping genetic modulators of amyloid plaque deposition in TgCRND8 transgenic mice"
  Hum. Mol. Genet. 2006 15: 2313-2323.
  
  

• Gervais F, Paquette J., Morissette C., Krzywkowski P., Yu M., Azzi M., Lacombe D., Kong X., Aman A., Laurin J. et al. 2006.
  "Targeting soluble Aß peptide with Tramiprosate for the treatment of brain amyloidosis."
  Neurobiol. Aging: 28/4: 537-547.
  
  

• Hazenberg, B.P.C., Bijzet, J., Butrimiene, I., Livneh, A., Lesnyak, O., Nasonov, E.L., Hawkins, P.N., Fillipwicz-Sosnowska, A., Obici, L., Gul, A., Wiland, P., Ozdogan, H., Gorevic, P.D., Dember, L.M., Skinner, M., Ben Maiz, H., Briand, R., Garceau, D., Hauck, W. 2005.
  "Impact of Fibrillex, an anti-amyloid product, on amyloid A (AA) protein content in abdominal fat tissue biopsies from patient's with AA amyloidosis: results from a pivotal international trial."
  Proceedings of the Annual European Congress of Rheumatology (EULAR), Vienna, Austria, June 8-11, 2005.
  
  

• Gorevic, .P D., Livneh, A., Dember, L. M., Skinner, M., Kaarela, K., Butrimiene, I., Hawkins, P. N., Hazenberg, B. P. C., Merlini, G., Obici, L., Benson, M. D., Ortiz, V., Filipowicz-Sosnowska, A., Wiland, P., Hunter, J. A., Briand, R., Garceau, D., Hauck, W. on the behalf of the FAST group. 2005.
  "Long-term safety and efficacy of Fibrillex, an anti-amyloid product, as a treatment for amyloid A (AA) amyloidosis: interim analysis of the open-label extension of the pivotal fast trial."
  Proceedings of the Annual European Congress of Rheumatology (EULAR), Vienna, Austria, June 8-11, 2005.
  
  

• Sebastiani, G., Morissette, C., Lagacé, C., Boulé, M., Ouellette, M.-J., McLaughlin, R.W., Lacombe, D., Gervais, F., and Tremblay, P. 2005.
  "The c-AMP-specific phosphodiesterase 4B mediates Aß-induced microglial activation. "
  Neurobiol. Aging: 27/5: 691-701.
  
  

• Gervais, F., Garceau, D., Aisen, P., and Gauthier, S. 2005.
  "GAG mimetics in Alzheimer's disease. In: Gauthier, S., Scheltens, P., and Cummings, J.L., Eds, Alzheimer's Disease and Related Disorders Annual 2005."
  Martin Dunitz, London, In Press.
  
  

• Dember, L., Gorevic, P., Benson, M., Dispenzieri, A., Hawkins, P, Hazenberg, B., Skinner, M., Hauck, W., on behalf of the FAST group. 2004.
  "GAG mimetics for systemic amyloidosis: design and progress of an international multi-center trial of NC-503 for amyloid A (AA) amyloidosis."
  J. Am. Soc. Nephrol. 15: 360A.
  
  

• Hauck, W., Dember, L.M., Hawkins, P.N., Hazenberg, B.P.C., Skinner, M., Bouwmeester, M.-C., Briand, R., Chicoine, É., Gurbindo, C., Hughes, L., Garceau, D., on behalf of the FAST group. 2004.
  "A prospective analysis of demography, etiology, and clinical findings of AA amyloidosis patients enrolled in the International Clinical Phase II/III Fibrillex study."
  Proceedings of the Xth International Symposium on Amyloid and Amyloidosis, Tours, France, In press.
  
  

• Hazenberg, B.P.C., Bijzet, J., Limburg, P.C., van Rijswijk, M.H., Garceau, D., and Fibrillex Amyloid Secondary Trial (FAST) Group. 2004.
  "Fat tissue analysis by Congo red method and by amyloid A protein qualification in clinical AA amyloidosis."
  Proceedings of the Xth International Symposium on Amyloid and Amyloidosis, Tours, France, In press.
  
  

• Morissette, C., Boulé, M., Tremblay, P., Gervais, F. 2004.
  "Inhibition of ß-amyloid peptide-induced microglial cell activation by glycosaminoglycans. "
  Proceedings of the Xth International Symposium on Amyloid and Amyloidosis, Tours, France, In press.
  
  

• Sebastiani, G., Morissette, C., Lagacé, C., Boulé, M., Ouellette, M.-J., McLaughlin, R.W., Lacombe, D., Gervais, F., Tremblay, P. 2004.
  "cAMP-specific phosphodiesterase 4B mediates Aß-induced microglial activation."
  Proceedings of the Xth International Symposium on Amyloid and Amyloidosis, Tours, France, In press.
  
  

• Dudal, S., Morissette, C., Lacombe, D., Tremblay, P., and Gervais, F. 2004.
  "Differences in the amyloid-ß induced inflammatory response in microglial from C57BL/6 and A/J strains of mice. "
  J. Neuroimmunol. 153: 26-35.
  
  

• Dudal, S., Krzywkovski, P., Paquette, J., Morissette, C., Lacombe, D., Tremblay, P., and Gervais, F. 2004.
  "Inflammation occurs early during Aß deposition process in TgCRND8 mice. "
  Neurobiol. Aging 25:861-871.
  
  

• Gervais, F., Morissette, C., and Kong, X. 2003.
  "Proteoglycans and amyloidogenic proteins in peripheral amyloidosis."
  Curr. Med. Chem.- Immun. Endoc. & Metab. Agents 3: 361-370.
  
  

• Chalifour R. J., McLaughlin, R. W., Lavoie, L., Morissette, C., Tremblay, N., Boulé, M., Sarazin, P., Stéa, D., Lacombe, D., and Tremblay, P. 2003.
  "Stereoselective interactions of peptide inhibitors with the ß-amyloid peptide."
  J. Biol. Chem. 278: 34874-34881.
  
  

• Tan, C. Y., Wainman, D. S., and Weaver, D. F. 2003.
  "N-, a-, and b-substituted 3-aminopropionic acids: design, synthesis and antiseizure activities."
  Bioorg. Med. Chem.11: 113-21.
  
  

• Gervais, F. and Tremblay, P. 2002. Immunotherapy in Alzheimer's disease. In: Gauthier, S. and Cummings, J.L., Eds,
  "Alzheimer's Disease and Related Disorders Annual 2002."
  Martin Dunitz, London, pp. 53-66.
  
  

• Chakfe, Y., Seguin, R., Antel, J. P., Morissette, C., Malo, D., Henderson, D., and Seguela, P. 2002.
  "ADP and AMP induce interleukin-1ß release from microglial cells through activation of ATP-primed P2X7 receptor channels."
  J. Neurosci. 22: 3061-3069.
  
  

• Zhang, Y., McLaughlin, R., Goodyer, C., and LeBlanc, A. 2002.
  "Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons."
  J. Cell Biol. 156: 519-529.
  
  

• Chalifour, R. J., Lavoie, L., Morissette, C. Boulé, M., McLaughlin, R. W., Sarazin, P., Stéa, D., Gervais, F. 2001.
  "Stereoselective peptide inhibitors of amyloid-ß(1-40) assembly."
  Eds. M. Bély and A. Apathy. Proc.IXth Int. Symp. Amyloidosis. David Apathy, Budapest, pp. 454-456.
  
  

• Chishti, M.A., Yang, D.S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., Turner, S., Lozza, G., Grilli, M., Kunicki, S., Morissette, C., Paquette, J., Gervais, F., Bergeron, C., Fraser, P.E., Carlson, G.A., George-Hyslop, P.S., and Westaway, D. 2001.
  "Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695."
  J. Biol. Chem. 276: 21562-21570.
  
  

• Dumery, L., Bourdel, F., Soussan, Y., Fialkowsky, A., Viale, S., Nicolas, P., and Reboud-Ravaux, M. 2001.
  "beta-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's Disease."
  Pathol. Biol. (Paris.) 49: 72-85.
  
  

• Dudal, S., Krzywkowski, P., Kunicki, S, Paquette, J., and Morissette, C. 2001.
  "Characterization of a model of hAPP transgenic mice: amyloid deposition and inflammation in the brain."
  Eds. M. Bély and A. Apathy. Proc.IXth Int. Symp. Amyloidosis. David Apathy, Budapest, pp. 457-459.
  
  

• Garceau, D., Gurbindo, C., Laurin, J. 2001.
  "Safety, tolerability and pharmacokinetic profile of Fibrillex™ (anti-AA amyloid agent) in healthy and renal impaired subjects."
  Eds. M. Bély and A. Apathy. Proc.IXth Int. Symp. Amyloidosis. David Apathy, Budapest, pp. 116-118.
  
  

• Gervais, F., Chalifour, R., Kong, X., Morissette, C., Paquette, J. 2001.
  "GAG mimetics: advance in multiple therapeutic areas."
  Eds. M. Bély and A. Apathy. Proc. IXth Int. Symp. Amyloidosis. David Apathy, Budapest, pp. 589-592.
  
  

• Gervais, F. 2001.
  "Amyloid-Those deadly fibrils."
  Eur. Biopharm. Rev. Autumn 2001: 40-42.
  
  

• Gervais, F., Chalifour, R., Garceau, D., Kong, X., Laurin, J., McLaughlin, R., Morissette, C., and Paquette, J. 2001.
  "Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. "
  Amyloid 8 (Suppl.): 28-35.
  
  

• Morissette, C., Caouras, V., and Gervais, F. 2001.
  "In vitro cytotoxicity assay for screening potential therapeutics for cerebral amyloid angiopathy disorder."
  Eds. M. Bély and A. Apathy. Proc.IXth Int. Symp. Amyloidosis. David Apathy, Budapest, pp. 451-453.
  
  

• Huang, T.H., Yang, D.S., Fraser, P.E., and Chakrabartty, A. 2000.
  "Alternate aggregation pathways of the Alzheimer beta -amyloid peptide. An in-vitro model of preamyloid."
  J. Biol. Chem. 275: 36436-36440.
  
  

• Huang, T.H., Yang, D.S., Plaskos, N.P., Go, S., Yip, C.M., Fraser, P.E., and Chakrabartty, A. 2000.
  "Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide."
  J. Mol. Biol. 297: 73-87.
  
  

• Keane, M.P. and Strieter, R.M. 2000.
  "Chemokine signaling in inflammation."
  Crit.Care Med. 28 (4 Suppl.): N13-26.
  
  

• Yang, D.S., McLaurin, J., Qin, K., Westaway, D., and Fraser, P.E. 2000.
  "Examining the zinc binding site of the amyloid-beta peptide."
  Eur. J. Biochem. 267: 6692-6698.
  
  

• Inoue, S., Kuroiwa, M., and Kisilevsky, R. 1999.
  "Basement membranes, microfibrils and beta amyloid fibrillogenesis in Alzheimer's disease: high resolution ultrastructural findings."
  Brain Res. Rev. 29: 218-231.
  
  

• Kisilevsky, R., Lemieux, L., Boudreau, L., Yang, D.S., and Fraser, P.E.. 1999.
  "New clothes for amyloid enhancing factor (AEF): silk as AEF."
  Amyloid 6: 98-106.
  
  

• McLaurin, J., Franklin, T., Kuhns, W.J., and Fraser, P.E.. 1999.
  "A sulfated proteoglycan aggregation factor mediates amyloid-beta peptide fibril formation and neurotoxicity."
  Amyloid 6: 233-243.
  
  

• McLaurin, J., Franklin, T., Zhang, X., Deng, J., and Fraser, P.E. 1999.
  "Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans: effects on fibril nucleation and growth."
  Eur. J. Biochem. 266: 1101-1110.
  
  

• Yang, D.S., Yip, C.M., Huang, T.H., Chakrabartty, A., and Fraser, P.E.. 1999.
  "Manipulating the amyloid-beta aggregation pathway with chemical chaperones."
  J. Biol. Chem. 274: 32970-32974.
  
  

• Inoue, S., Kuroiwa, M., Tan, R., and Kisilevsky, R. 1998.
  "A high resolution ultrastructural comparison of isolated and in situ murine AA amyloid fibrils."
  Amyloid 5: 99-110.
  
  

• Inoue, S., Kuroiwa, M., Saraiva, M.J., Guimaraes, A., and Kisilevsky, R. 1998.
  "Ultrastructure of familial amyloid polyneuropathy amyloid fibrils: examination with high-resolution electron microscopy."
  J. Struct. Biol. 124: 1-12.
  
  

• Knight, J.L. and Weaver, D.F. 1998.
  "A computational quantitative structure-activity relationship study of carbamate anticonvulsants using quantum pharmacological methods."
  Seizure 7: 347-354.
  
  

• Kisilevsky, R. and Fraser, P.E. 1997.
  "Aß amyloidogenesis: Unique, or variation on a systemic theme?"
  Critical Rev. Biochem. Mol. Biol. 32: 361-404.
  
  

• Kisilevsky, R. 1997.
  "Can deposition of amyloid be prevented in Alzheimer's disease."
  Ann. NY Acad. Sci. 856: 117-127.
  
  

• Inoue, S., Hultin, P.G., Szarek, W.A., and Kisilevsky, R. 1996.
  "Effect of poly(Vinylsulfonate) on murine AA amyloid : a high-resolution ultrastructural study."
  Lab. Invest. 74: 1081-1090.
  
  

• Kisilevsky, R. 1996.
  "Anti-amyloid drugs: Potential in the treatment of diseases associated with aging."
  Drugs & Aging 8: 75-83.
  
  

• Kisilevsky, R., Lemieux, L.J., Fraser, P.E., Kong, X., Hultin, P.G., and Szarek, W.A.. 1995.
  "Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease."
  Nat. Med. 1: 143-148.

Notre site est optimisé pour IE4+ pour une résolution de 1024×768.
Tout contenu, copyright © 1998-2007 Neurochem Inc.
Modalités, conditions et mise en garde.